Breast Cancer

, Volume 24, Issue 2, pp 319–325

Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial

  • Martin Eichler
  • Susanne Singer
  • Wolfgang Janni
  • Nadia Harbeck
  • Brigitte Rack
  • Doris Augustin
  • Arthur Wischnik
  • Marion Kiechle
  • Johannes Ettl
  • Christoph Scholz
  • Visnja Fink
  • Lukas Schwentner
Original Article

DOI: 10.1007/s12282-016-0706-3

Cite this article as:
Eichler, M., Singer, S., Janni, W. et al. Breast Cancer (2017) 24: 319. doi:10.1007/s12282-016-0706-3

Abstract

Background

Health-related quality of life (QoL) is a self-assessed construct indicating how people feel in regard to aspects of their health. Performance status (PS) is evaluated by the treating physician. We examined whether pretreatment QoL and PS are related to subsequent treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy.

Methods

We conducted a prospective cohort study with data from a randomized phase III trial comparing FEC- and EC-DOC-chemotherapy in patients with primary breast cancer (ADEBAR). We examined the patient’s request to discontinue the study, discontinuation due to toxicity, the prolongation of therapy, and dose reduction. Baseline QoL was assessed using the EORTC QLQ-C30. PS was evaluated using the Eastern Cooperative Oncology Group Scale (ECOG). Four QoL scales were selected prior to analysis as outcomes: global health, physical functioning, emotional functioning, and fatigue. Multivariate binary logistic regression analyses were used to test for differences within the independent variables.

Main results

1322 patients were included. 1094 (82.8 %) patients completed therapy according to protocol. 6.3 % stopped therapy due to toxicity and 4.4 % refused treatment. Global health was not related to any of the four QoL outcomes. Physical functioning had the strongest impact on QoL, when comparing the fittest group to the lowest quintile [OR 2.14 (95 % CI 1.00–4.60)]. ECOG 0 compared to worse than 1 was strongly correlated to therapy discontinuation due to toxicity [OR 20.15 (95 % CI 9.48–42.83)] and treatment refusal [OR 8.32 (95 % CI 3.81–18.14)].

Conclusions

Pretreatment QoL, especially physical functioning, is associated with subsequent therapy discontinuation due to toxicity and with changes of the treatment protocol. Pretreatment performance status is strongly associated with therapy discontinuation due to toxicity and with treatment refusal.

Keywords

Quality of life Performance status Treatment discontinuation Breast cancer Chemotherapy 

Supplementary material

12282_2016_706_MOESM1_ESM.docx (36 kb)
Supplementary material 1 (DOCX 29 kb)

Copyright information

© The Japanese Breast Cancer Society 2016

Authors and Affiliations

  • Martin Eichler
    • 1
  • Susanne Singer
    • 1
  • Wolfgang Janni
    • 2
  • Nadia Harbeck
    • 3
  • Brigitte Rack
    • 3
  • Doris Augustin
    • 4
  • Arthur Wischnik
    • 5
  • Marion Kiechle
    • 6
  • Johannes Ettl
    • 6
  • Christoph Scholz
    • 2
  • Visnja Fink
    • 2
  • Lukas Schwentner
    • 2
  1. 1.Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI)University Medical Center of the Johannes Gutenberg University MainzMainzGermany
  2. 2.Department of Gynecology and ObstetricsUniversity Hospital UlmUlmGermany
  3. 3.Breast Center, Department of Gynecology and ObstetricsLudwig-Maximilian-University MunichMunichGermany
  4. 4.Clinics Deggendorf Mammacenter OstbayernDeggendorfGermany
  5. 5.Breast CenterClinics AugsburgAugsburgGermany
  6. 6.Department of Gynecology and Obstetrics, Klinikum Rechts der IsarTechnical University MunichMunichGermany

Personalised recommendations